Taiwan-based Formosa Pharmaceuticals Inc (TPE:6838) announced on Thursday that it has signed an exclusive licensing agreement with DÁVI Farmacêutica in Portugal.
The agreement covers exclusive rights to the commercialisation of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a marketed innovative medicine for the treatment of inflammation and pain following ocular surgery.
Approved by the US Food and Drug Administration (FDA) in March 2024, the product was launched in the United States in September 2024.
The DÁVI licensing agreement includes an upfront payment, commercialisation and sales milestones, and additional considerations throughout the term of the contract.
Erick Co, Formosa Pharmaceuticals' president and CEO, said: "This partnership with DÁVI Farmacêutica marks our first entry into a competitive EU market, opening the door for growth into other EU territories. DÁVI's experience and commitment to novel ophthalmic therapies is steadily apparent and Formosa Pharma appreciates their recognition of APP13007 as a worthy offering to patients recovering from ocular surgery."
Karyopharm seeks accelerated FDA approval for selinexor–ruxolitinib in myelofibrosis
Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30
Zambon receives European Commission approval for Hopledo in Parkinson's disease
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
Annovis Bio schedules corporate update webinar for next week
Cellenkos' CK0803 granted US FDA Fast Track designation for ALS
Labcorp to offer FDA-cleared pTau-217 blood test for Alzheimer's assessment
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
European Commission grants orphan designation for Vanda's imsidolimab
United Therapeutics wins FDA acceptance for ralinepag PAH filing
Acadia wins EU approval for DAYBU as first treatment for Rett syndrome